宁波巯晟新材料有限公司
首页 产品目录 产品目录(简版) 公司动态 企业认证 联系我们

Heck偶联专用——QSM112多齿巯基硅胶,破解烯烃化合成除钯瓶颈

发布人:宁波巯晟新材料有限公司

发布日期:2026/3/28 9:32:56

Heck偶联反应是实现烯烃官能化、构建复杂杂环药物的关键技术,在抗感染药、抗肿瘤药、心脑血管药物等原料药合成中不可或缺。该反应多在DMF、DMAc等高极性溶剂中进行,反应体系复杂,钯催化剂易与产物形成稳定络合物,常规除钯手段难以剥离,极易造成钯残留超标;同时传统除杂材料易出现溶胀、破损,不仅除钯效率低下,还会损耗产品收率,影响产物纯度,制约工业化生产效率。
巯晟QSM112多齿巯基硅胶,针对Heck偶联反应体系特性优化升级,多齿螯合基团能快速精准捕获溶解态、络合态钯金属,打破钯与产物的稳定结合,实现深度除钯。产品具备优异的高极性溶剂耐受性,在DMF、DMAc、乙腈等体系中依旧保持稳定结构,不溶胀、不破碎、无官能团溶出,杜绝二次污染,完美适配Heck偶联的工艺环境。
相较于传统除钯材料,QSM112吸附速率更快、处理周期更短,常温搅拌即可完成高效除钯,无需高温高压等严苛条件,简化生产流程。经药企实际应用验证,该产品可将Heck反应中间体钯残留从数百ppm降至0.5ppm以下,保证API产品纯度达标,有效减少收率损耗,提升溶剂回收效率,适配间歇式生产与连续化生产场景,助力药企优化纯化工艺,提升产品质量,满足高端原料药的生产与申报要求,打通医药合成工业化量产链路。
Heck coupling reaction is a key technology to realize olefin functionalization and construct complex heterocyclic drugs, which is indispensable in the synthesis of APIs such as anti-infective drugs, antitumor drugs and cardiovascular and cerebrovascular drugs. This reaction is mostly carried out in high-polarity solvents such as DMF and DMAc, the reaction system is complex, palladium catalyst is easy to form a stable complex with the product, conventional palladium removal methods are difficult to strip, and it is very easy to cause excessive palladium residue. At the same time, traditional impurity removal materials are prone to swelling and damage, which not only has low palladium removal efficiency, but also reduces product yield, affects product purity, and restricts industrial production efficiency.
Qiusheng QSM112 Multi-tooth Mercapto Silica Gel is optimized and upgraded according to the characteristics of Heck coupling reaction system. The multi-tooth chelating group can quickly and accurately capture dissolved and complexed palladium metals, break the stable combination of palladium and products, and realize deep palladium removal. The product has excellent high-polarity solvent tolerance, maintains a stable structure in DMF, DMAc, acetonitrile and other systems, no swelling, no breakage, no functional group dissolution, eliminates secondary pollution, and perfectly adapts to the process environment of Heck coupling.
Compared with traditional palladium removal materials, QSM112 has faster adsorption rate and shorter treatment cycle. It can complete efficient palladium removal by stirring at room temperature without harsh conditions such as high temperature and high pressure, simplifying the production process. Verified by practical application of pharmaceutical enterprises, this product can reduce the palladium residue of Heck reaction intermediates from hundreds of ppm to less than 0.5ppm, ensure the purity of API products, effectively reduce yield loss, improve solvent recovery efficiency, adapt to batch production and continuous production scenarios, help pharmaceutical enterprises optimize purification processes, improve product quality, meet the production and declaration requirements of high-end APIs, and open up the industrial mass production link of pharmaceutical synthesis.


相关新闻资讯

RMC-6236:RAS(ON)多选择性抑制剂的合成与纯化工艺突破

2026/04/13

RMC-6236突破性抑制RAS突变,挑战"不可成药"靶点!这款首创性药物通过独特机制靶向多种KRAS突变,已获FDA突破性疗法认定。其复杂合成涉及12步反应,尤其钯催化大环构建与严苛的金属杂质控制成为关键挑战——钯残留需控制在2ppm以下,比注射剂标准严格5倍。内容由AI智能生成有用一、RMC-6236:重新定义RAS靶向治疗RAS基因突变是肿瘤学领域最棘手的难题之一。约27%的实体瘤携带RAS

曲拉西利的合成与纯化:从实验室到临床级原料药的关键工艺控制

2026/04/13

一、曲拉西利:骨髓保护领域的突破性药物曲拉西利(Trilaciclib,商品名 Cosela®)是全球首个获批的骨髓保护药物,由G1 Therapeutics开发,2021年获FDA批准上市。作为一种短效CDK4/6抑制剂,曲拉西利通过在化疗前短暂阻滞造血干细胞于G1期,显著降低化疗引起的骨髓抑制,减少中性粒细胞减少症的发生率。其化学结构为含三嗪核心骨架的多环化合物,分子式C₂₄H₃₂N₈O,分子

从杂质控制到收率提升,瑞米布替尼工艺优化:巯基硅胶破解钯残留与有机杂质难题

2026/04/13

一、工艺分析瑞米布替尼合成过程中,铃木偶联反应难度较高,反应初期易出现快速温升现象,存在安全隐患,在工业化放大生产时需重点关注安全管控。注册路线建议:以502496-33-5、1613413-65-2、1787294-51-2和79-10-7为起始物料,采用6步反应作为注册路线。工艺开发注意事项:该工艺中有多个步骤需通过产品制备纯化获得,在工艺开发过程中应尽量规避此类操作,以降低工艺复杂度和成本,